ANDA 77517, held by Chartwell Rx. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77517 (Ondansetron Hydrochloride), held by Chartwell Rx, was first approved by FDA on Jun 25, 2007, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2007 | Original application | Approved | None posted |
| Ondansetron HydrochlorideEQ 4MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Ondansetron HydrochlorideEQ 8MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Ondansetron HydrochlorideEQ 24MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Mar 8, 2018 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 12, 2013 | Supplement 3Labeling | Approved | None posted |
| Apr 30, 2012 | Supplement 5Labeling | Approved | None posted |
| Jun 25, 2007 | Original application | Approved | None posted |
| Jun 25, 2007 | Supplement 1 | Approved | None posted |
| Jun 25, 2007 | Supplement 2 | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters